Back to Faculty
Co-Chair

Edward Garon

MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

2026 Sessions

Plenary: Biomarkers Beyond Boundaries: Opportunities and Challenges of Biology Crossing Histologic Categorization

Presenter

Saturday, March 14 8:10–8:55 AM
Room Royal Ballroom 2
Co-Chair

Edward Garon

MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Case-Based Treatment Strategies in Lung Cancers

Moderator

Panelist

Saturday, March 14 11:10–11:55 AM
Room Royal Ballroom 3/4
Co-Chair

Edward Garon

MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Co-Chair

Corey Langer

MD, FACP
Director of Thoracic Oncology
Abramson Cancer Center, Hospital of the University of Pennsylvania

Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.
Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he helps lead clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC.
Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). Since 2016, he has been Editor-in-Chief of the International Lung Cancer News (ILCN) under the aegis of the IASLC.
He has authored or co-authored over 220 peer-reviewed papers in thoracic oncology.

Faculty

Kelsey Pan

MD, MPH
Assistant Professor, Department of Medical Oncology
Emory University Winship Cancer Institute

Kelsey Pan is a Thoracic Medical Oncologist and Assistant Professor of Medicine at Emory University Winship Cancer Center. Her interests within thoracic malignancies include clinical outcomes of novel targeted therapies in oncogene-driven NSCLC, CNS metastases and LMD. She completed hematology/ oncology fellowship at MD Anderson Cancer Center, where she served as a Chief Fellow for 2 years. She has participated in various workshops focused on clinical research and trials development, such the FDA/ASCO Fellows' Workshop, AACR/ASCO Methods in Clinical Research, and EGFR Resisters Research Summit. She has presented her research in thoracic malignancies at various national and international conferences, including IASLC World Conference in Lung Cancer and Targeted Therapies of Lung Cancer. As a new faculty and clinical investigator, she is interested in continuing her work in treating CNS metastases and actionable genomic alterations in NSCLC by designing clinical trials of novel therapies with enhanced CNS penetrance.

Faculty

Luis Raez

MD, FASCO
Chief Scientific Officer & Medical Director
Memorial Cancer Institute/Florida Atlantic University

Luis E. Raez, MD, FASCO, FACP, FCCP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the Vice-President of the Florida Society of Clinical Oncology (FLASCO) 2017-19 and President 2019-2021.
He designs phase I-III clinical trials with new targeted agents and immunotherapy. Dr. Raez does translational research and clinical research. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America, Africa and Asia.
Chairman of the IASLC Latin American Group (LATAM) since 2018; Chair of the IASLC Membership Committee from 2015-2018; International Chair of the IASLC-Latin-American Meeting (LALCA) since 2014; Chairman for the "Miami Best of ASCO" since 2014, Chair and Founder of the "Miami Cancer Meeting (MCM)" since 2002, Co-Chairman at the "Puerto Rico Fall Cancer Symposia (FCS)" since 2010.
He is American Board Certified in: Internal Medicine and Medical Oncology.
He is a member and serves in several committees at: AACR, OLA, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, SLACOM, FLASCO.

Faculty

Edgardo Santos

MD, FACP, FASCO
Medical Director, Broward County and Physician Lead, TOI Lung Cancer Center of Excellence
The Oncology Institute of Hope and Innovation

Edgardo S. Santos Castillero, MD, FACP, FASCO practices at The Oncology Institute (TOI) of Hope and Innovation and is Clinical Associate Professor at Charles E. Schmidt College of Medicine/Florida Atlantic University. Dr. Santos is the Medical Director at Broward County, Florida for TOI, the Physician Lead for TOI Lung Cancer Center of Excellence and the President of Florida Society of Clinical Oncology (FLASCO). He is also an active member of the Membership Committee as well as Editorial Group member IASLC Lung Cancer News (ILCN) of the International Association for the Study of Lung Cancer (IASLC), member of the Evidence-based Medicine Committee, Head and Neck Guideline Advisory Group and member of the 2023, 2024 and 2025 ASCO-SEP Item Writing Task Force for the American Society of Clinical Oncology (ASCO). Dr. Santos earned his M.D. in 1994 at the University of Panama, School of Medicine, Republic of Panama. Dr. Santos has authored or co-authored more than 100 manuscripts in peer-reviewed journals and serves as reviewer for several scientific publications. His focus and expertise in on lung cancer diagnosis, management, and research. Dr. Santos is a former faculty member of University of Miami Miller School of Medicine, Miami, Florida where he held an academic rank as an Associate Professor of Medicine (2008-2012) and Tulane University Health Sciences Center, New Orleans, Louisiana (2004-2008). He is an active member of ACP, ASCO, ASH, AACR, ESMO, IASLC, OLA, and ILBS.
General Session

Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if...

  • Moderator
    • Edward Garon, MD, MS
    • Corey Langer, MD, FACP
  • Presenter
    • Kelsey Pan, MD, MPH
    • Estelamari Rodriguez, MD, MPH
Lung Cancers

Neoadjuvant Only

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care.

The speaker will review clinical trial data supporting preoperative systemic approaches, including chemotherapy and immunotherapy, and their impact on pathologic response and surgical outcomes. The discussion will address patient selection, timing of surgery, and safety considerations, and revisit the benefits and limitations of neoadjuvant strategies in resectable lung cancer.

Presenter

Saturday, March 14 4:25–4:45 PM
Room Royal Ballroom 3/4
Faculty

Kelsey Pan

MD, MPH
Assistant Professor, Department of Medical Oncology
Emory University Winship Cancer Institute

Kelsey Pan is a Thoracic Medical Oncologist and Assistant Professor of Medicine at Emory University Winship Cancer Center. Her interests within thoracic malignancies include clinical outcomes of novel targeted therapies in oncogene-driven NSCLC, CNS metastases and LMD. She completed hematology/ oncology fellowship at MD Anderson Cancer Center, where she served as a Chief Fellow for 2 years. She has participated in various workshops focused on clinical research and trials development, such the FDA/ASCO Fellows' Workshop, AACR/ASCO Methods in Clinical Research, and EGFR Resisters Research Summit. She has presented her research in thoracic malignancies at various national and international conferences, including IASLC World Conference in Lung Cancer and Targeted Therapies of Lung Cancer. As a new faculty and clinical investigator, she is interested in continuing her work in treating CNS metastases and actionable genomic alterations in NSCLC by designing clinical trials of novel therapies with enhanced CNS penetrance.

Perioperative Therapy

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care.

Examine perioperative therapy strategies for patients with resectable lung cancer, incorporating both neoadjuvant and adjuvant treatment approaches. Faculty will review evidence demonstrating how perioperative systemic therapy may improve recurrence risk and long-term survival outcomes, while addressing sequencing considerations, toxicity management, and coordination of care across the surgical and medical oncology settings.

Presenter

Saturday, March 14 4:45–5:05 PM
Room Royal Ballroom 3/4
Faculty

Estelamari Rodriguez

MD, MPH
Clinical Research Lead Thoracic Site Disease Group
University of Miami Miller School of Medicine

Dr. Estelamari Rodriguez is Co-Lead of the Thoracic Site Disease Group and Associate Director of Community Outreach and of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is an active member of the Sylvester Experimental Therapeutics Program and has served as principal investigator of several early phase and cooperative group clinical trials in the United States. She is a member of the ECOG Thoracic Committee and Chair-elect of the ASCO Evidence Based Medicine Committee. Dr. Rodriguez received her bachelors degree from Columbia College and her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain. She has given numerous international lectures as invited speaker on issues related to lung cancer treatment and healthcare disparities.
General Session

Management of Oligo-Remnant Metastatic Lung Cancer: Systemic Therapy Alone vs Systemic Therapy Plus Local Ablation

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival...

  • Moderator
    • Edward Garon, MD, MS
  • Presenter
    • Corey Langer, MD, FACP
    • Edgardo Santos, MD, FACP, FASCO
Lung Cancers

Systemic Therapy Alone

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival and long-term outcomes. The discussion will review patient selection, timing of intervention, and available local treatment modalities. Speakers will discuss their experience with integrating systemic and local approaches in contemporary lung cancer care.

Review evidence supporting continued systemic treatment for cancer control, including outcomes with targeted therapy, immunotherapy, and combination regimens. The speaker will address durability of response and scenarios in which local interventions may be deferred. Participants will gain insight into optimizing systemic therapy strategies for patients with limited residual metastatic disease.

Presenter

Sunday, March 15 11:10–11:30 AM
Room Royal Ballroom 3/4
Co-Chair

Corey Langer

MD, FACP
Director of Thoracic Oncology
Abramson Cancer Center, Hospital of the University of Pennsylvania

Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.
Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he helps lead clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC.
Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). Since 2016, he has been Editor-in-Chief of the International Lung Cancer News (ILCN) under the aegis of the IASLC.
He has authored or co-authored over 220 peer-reviewed papers in thoracic oncology.

Systemic Therapy Plus Local Ablation

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival and long-term outcomes. The discussion will review patient selection, timing of intervention, and available local treatment modalities. Speakers will discuss their experience with integrating systemic and local approaches in contemporary lung cancer care.

Explore the use of systemic therapy combined with local ablative approaches in the management of oligo-remnant metastatic lung cancer by reviewing clinical evidence supporting the addition of local treatments, such as stereotactic body radiation therapy or surgical ablation, to improve disease control. Discussion will address integration with ongoing systemic therapy, and cover multimodal strategies for enhancing long-term outcomes in these patients.

Presenter

Sunday, March 15 11:30–11:50 AM
Room Royal Ballroom 3/4
Faculty

Edgardo Santos

MD, FACP, FASCO
Medical Director, Broward County and Physician Lead, TOI Lung Cancer Center of Excellence
The Oncology Institute of Hope and Innovation

Edgardo S. Santos Castillero, MD, FACP, FASCO practices at The Oncology Institute (TOI) of Hope and Innovation and is Clinical Associate Professor at Charles E. Schmidt College of Medicine/Florida Atlantic University. Dr. Santos is the Medical Director at Broward County, Florida for TOI, the Physician Lead for TOI Lung Cancer Center of Excellence and the President of Florida Society of Clinical Oncology (FLASCO). He is also an active member of the Membership Committee as well as Editorial Group member IASLC Lung Cancer News (ILCN) of the International Association for the Study of Lung Cancer (IASLC), member of the Evidence-based Medicine Committee, Head and Neck Guideline Advisory Group and member of the 2023, 2024 and 2025 ASCO-SEP Item Writing Task Force for the American Society of Clinical Oncology (ASCO). Dr. Santos earned his M.D. in 1994 at the University of Panama, School of Medicine, Republic of Panama. Dr. Santos has authored or co-authored more than 100 manuscripts in peer-reviewed journals and serves as reviewer for several scientific publications. His focus and expertise in on lung cancer diagnosis, management, and research. Dr. Santos is a former faculty member of University of Miami Miller School of Medicine, Miami, Florida where he held an academic rank as an Associate Professor of Medicine (2008-2012) and Tulane University Health Sciences Center, New Orleans, Louisiana (2004-2008). He is an active member of ACP, ASCO, ASH, AACR, ESMO, IASLC, OLA, and ILBS.
General Session

Treatment After Progression on Chemoimmunotherapy in Lung Cancer: Continuing Standard Cytotoxic Therapy vs Transitioning to Alternative Approaches

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line...

  • Moderator
    • Edward Garon, MD, MS
    • Corey Langer, MD, FACP
  • Presenter
    • Luis Raez, MD, FASCO
    • Daniel Rosas, MD
Lung Cancers

Continuing Standard Cytotoxic Therapy

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting.

This session will focus on the role of continuing standard cytotoxic therapy for patients with lung cancer who experience disease progression after frontline chemoimmunotherapy. Faculty will review evidence supporting commonly used second-line chemotherapy options, including expected efficacy and toxicity profiles. Learners will gain perspective on when traditional cytotoxic approaches remain an appropriate and effective strategy after chemoimmunotherapy failure.

Presenter

Sunday, March 15 2:55–3:15 PM
Room Royal Ballroom 2
Faculty

Luis Raez

MD, FASCO
Chief Scientific Officer & Medical Director
Memorial Cancer Institute/Florida Atlantic University

Luis E. Raez, MD, FASCO, FACP, FCCP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the Vice-President of the Florida Society of Clinical Oncology (FLASCO) 2017-19 and President 2019-2021.
He designs phase I-III clinical trials with new targeted agents and immunotherapy. Dr. Raez does translational research and clinical research. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America, Africa and Asia.
Chairman of the IASLC Latin American Group (LATAM) since 2018; Chair of the IASLC Membership Committee from 2015-2018; International Chair of the IASLC-Latin-American Meeting (LALCA) since 2014; Chairman for the "Miami Best of ASCO" since 2014, Chair and Founder of the "Miami Cancer Meeting (MCM)" since 2002, Co-Chairman at the "Puerto Rico Fall Cancer Symposia (FCS)" since 2010.
He is American Board Certified in: Internal Medicine and Medical Oncology.
He is a member and serves in several committees at: AACR, OLA, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, SLACOM, FLASCO.

Transitioning to Alternative Approaches

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting.

Examine strategies for transitioning to alternative approaches beyond standard cytotoxic therapy in patients with progressive lung cancer. Speakers will review emerging treatment options, including targeted therapies, antibody-drug conjugates, novel immunotherapy strategies, and clinical trial opportunities. The discussion will address biomarker-driven decision-making, safety considerations, and patient selection, giving participants insight into how innovative therapeutic approaches may improve outcomes after chemoimmunotherapy failure.

Presenter

Sunday, March 15 3:15–3:35 PM
Room Royal Ballroom 2
Faculty

Daniel Rosas

MD
Chief Fellow. Hematology Oncology
Memorial Cancer Institute

Dr. Daniel Rosas is a Hematology–Oncology fellow physician and Chief Fellow at Memorial Cancer Institute. He earned his medical degree from CES University in Medellín, Colombia, and completed internal medicine residency training at the University of Texas Health Science Center at San Antonio. He is currently pursuing advanced subspecialty training in both malignant hematology and solid tumor oncology, with a particular focus on thoracic oncology. Dr. Rosas is committed to delivering evidence-based, compassionate care and is especially passionate about patient education and empowerment. He emphasizes open, transparent communication, shared decision-making, and clear explanation of complex treatment options so that patients and families can participate meaningfully in care planning. His goal is to improve outcomes while supporting quality of life throughout the cancer journey.
General Session

Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if...

  • Moderator
    • Edward Garon, MD, MS
    • Corey Langer, MD, FACP
  • Presenter
    • Jamie Chaft, MD
    • Estelamari Rodriguez, MD, MPH
Lung Cancers

Neoadjuvant Only

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care.

The speaker will review clinical trial data supporting preoperative systemic approaches, including chemotherapy and immunotherapy, and their impact on pathologic response and surgical outcomes. The discussion will address patient selection, timing of surgery, and safety considerations, and revisit the benefits and limitations of neoadjuvant strategies in resectable lung cancer.

Debate Speaker

Saturday, September 26 10:05–10:25 AM
Faculty

Jamie Chaft

MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center

Jamie E Chaft, MD is an Attending Physician at Mememorial Sloan Kettering Cancer Center where she serves as the Director of Early Stage Lung Cancer Research. She designs and leads clinical trials striving to improve the cure rates in early stage lung cancers. In such a capacity, she serves as Study Chair for the NCTN trial of adjuvant nivolumab within the ALCHEMIST program and co-lead of the LCRF LEADER study bringing personalized neoadjuvant therapies to patients with resectable lung cancer. Dr. Chaft's career is committeed to moving drugs shown to have promise in more advanced lung cancers into the early stage setting.

Perioperative Therapy

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care.

Examine perioperative therapy strategies for patients with resectable lung cancer, incorporating both neoadjuvant and adjuvant treatment approaches. Faculty will review evidence demonstrating how perioperative systemic therapy may improve recurrence risk and long-term survival outcomes, while addressing sequencing considerations, toxicity management, and coordination of care across the surgical and medical oncology settings.

Debate Speaker

Saturday, September 26 10:25–10:45 AM
Faculty

Estelamari Rodriguez

MD, MPH
Clinical Research Lead Thoracic Site Disease Group
University of Miami Miller School of Medicine

Dr. Estelamari Rodriguez is Co-Lead of the Thoracic Site Disease Group and Associate Director of Community Outreach and of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is an active member of the Sylvester Experimental Therapeutics Program and has served as principal investigator of several early phase and cooperative group clinical trials in the United States. She is a member of the ECOG Thoracic Committee and Chair-elect of the ASCO Evidence Based Medicine Committee. Dr. Rodriguez received her bachelors degree from Columbia College and her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain. She has given numerous international lectures as invited speaker on issues related to lung cancer treatment and healthcare disparities.
General Session

First-Line Strategies in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: Monotherapy Approaches vs Combination Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with...

  • Moderator
    • Edward Garon, MD, MS
    • Corey Langer, MD, FACP
  • Presenter
    • Eric Singhi, MD
    • Helena Yu, MD
Lung Cancers

Monotherapy Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with additional modalities improves long-term outcomes. The discussion will highlight efficacy, toxicity, resistance patterns, and sequencing considerations across available approaches. Presenters will provide expert perspective on integrating evolving clinical evidence into real-world treatment decisions.

Debate Speaker

Saturday, September 26 3:30–3:50 PM
Faculty

Helena Yu

MD
Associate Attending
Memorial Sloan Kettering Cancer Center

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Yu is an Attending Physician and Professor at Memorial Sloan Kettering Cancer Center and Research Director of the Thoracic Oncology Service. She sees patients with thoracic malignancies and oversees the clinical and translational research program for EGFR-mutant lung cancers. As Research Director, she oversees the research program for the thoracic service. She went to Cornell for college, medical school at University of Michigan Medical School, did her internal medicine residency at Hospital of the University of Pennsylvania, and did her oncology fellowship at Memorial Sloan Kettering Cancer Center.

Combination Approaches

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with additional modalities improves long-term outcomes. The discussion will highlight efficacy, toxicity, resistance patterns, and sequencing considerations across available approaches. Presenters will provide expert perspective on integrating evolving clinical evidence into real-world treatment decisions.

Debate Speaker

Saturday, September 26 3:50–4:10 PM
Faculty

Eric Singhi

MD
Assistant Professor
MD Anderson Cancer Center

Dr. Eric K. Singhi is an Assistant Professor and Thoracic Medical Oncologist at the University of Texas MD Anderson Cancer Center. He completed his Internal Medicine residency at Vanderbilt University and served as Chief Hematology/Oncology fellow at MD Anderson during his training.

As faculty at MD Anderson, Dr. Singhi specializes in patient education research and young onset lung cancer research. He serves as the medical oncology lead for the MD Anderson Young-Onset Lung Cancer Program, Patient Safety and Quality Officer for the Thoracic Medical Oncology Service Line, Director of Thoracic Research for the MD Anderson Cancer Network, and Director of the Thoracic Medical Oncology rotation for the MD Anderson medical oncology fellowship program. Nationally, he serves on the ASCO NSCLC Guidelines Committee, and Internationally on the IASLC Communications Committee.
General Session

Management of Oligo-Remnant Metastatic Lung Cancer: Systemic Therapy Alone vs Systemic Therapy Plus Local Ablation

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival...

  • Moderator
    • Edward Garon, MD, MS
  • Presenter
    • Sarah Goldberg, MD, MPH
Lung Cancers

Systemic Therapy Alone

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival and long-term outcomes. The discussion will review patient selection, timing of intervention, and available local treatment modalities. Speakers will discuss their experience with integrating systemic and local approaches in contemporary lung cancer care.

Review evidence supporting continued systemic treatment for cancer control, including outcomes with targeted therapy, immunotherapy, and combination regimens. The speaker will address durability of response and scenarios in which local interventions may be deferred. Participants will gain insight into optimizing systemic therapy strategies for patients with limited residual metastatic disease.

Debate Speaker

Sunday, September 27 10:05–10:25 AM
Faculty

Chinmay Jani

Systemic Therapy Plus Local Ablation

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival and long-term outcomes. The discussion will review patient selection, timing of intervention, and available local treatment modalities. Speakers will discuss their experience with integrating systemic and local approaches in contemporary lung cancer care.

Explore the use of systemic therapy combined with local ablative approaches in the management of oligo-remnant metastatic lung cancer by reviewing clinical evidence supporting the addition of local treatments, such as stereotactic body radiation therapy or surgical ablation, to improve disease control. Discussion will address integration with ongoing systemic therapy, and cover multimodal strategies for enhancing long-term outcomes in these patients.

Debate Speaker

Sunday, September 27 10:25–10:45 AM
Faculty

Sarah Goldberg

MD, MPH

Precision Treatment Pathways in NSCLC: A Multidisciplinary Roundtable on Rare and Actionable Mutations

Supported by an educational grant from Revolution Medicines, Inc.

Moderator

Sunday, September 27 10:50–11:35 AM
Co-Chair

Edward Garon

MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Case Discussions in Lung Cancers

Moderator

Panelist

Sunday, September 27 3:30–4:15 PM
Co-Chair

Edward Garon

MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Faculty

Chinmay Jani

Faculty

Joshua Sabari

MD
Assistant Professor of Medicine
NYU Langone Health Perlmutter Cancer Center

Dr. Sabari is an Assistant Professor of Medicine, Thoracic Medical Oncologist and member of the Phase I Experimental Therapeutics Group in the Department of Medical Oncology at New York University School of Medicine, NYU Langone Health Perlmutter Cancer Center. Dr. Sabari is the Medical Director for the inpatient Hematology and Oncology Service at NYU Langone Health. Dr. Sabari’s research focus includes targeted therapy drug development in non-small cell and small cell lung cancer.
Back to top